Our investments

Pharnext

Pharnext, a biopharmaceutical company specialised in the development of innovative treatments based on PleotherapyTM for serious neurological diseases such as Alzheimer’s and Carcot-Marie-Tooth. Pharnext was founded in 2007 by an internationally renowned team led by Professor Daniel Cohen, author of the first human genome map. Truffle Capital contributed to the creation of Pharnext in 2007.

Dr Philippe Pouletty is a Board member.

www.pharnext.com